Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Lindsay McCaw"'
Publikováno v:
Cancer Medicine, Vol 8, Iss 4, Pp 1540-1550 (2019)
Abstract Methods to deepen clinical responses to ibrutinib are needed to improve outcomes for patients with chronic lymphocytic leukemia (CLL). This study aimed to determine the safety and efficacy of combining a janus kinase (JAK)‐inhibitor with i
Externí odkaz:
https://doaj.org/article/5098968abc7341209bb93fc03dcaa1f2
Publikováno v:
EBioMedicine, Vol 15, Iss C, Pp 24-35 (2017)
Recent studies suggest there is a high incidence of elevated low-density lipoprotein (LDL) levels in Chronic Lymphocytic Leukemia (CLL) patients and a survival benefit from cholesterol-lowering statin drugs. The mechanisms of these observations and t
Externí odkaz:
https://doaj.org/article/c4504ff0de964b419ef1fd3a07a5b0ef
Autor:
David E. Spaner, Guizhei Wang, Lindsay McCaw, Yanmei Li, Patricia Disperati, Mary-Ann Cussen, Yonghong Shi
Publikováno v:
Haematologica, Vol 101, Iss 5 (2016)
Externí odkaz:
https://doaj.org/article/eecd683c0873494ca7126556be18998b
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 8, Iss 4, Pp 1540-1550 (2019)
Cancer Medicine, Vol 8, Iss 4, Pp 1540-1550 (2019)
Methods to deepen clinical responses to ibrutinib are needed to improve outcomes for patients with chronic lymphocytic leukemia (CLL). This study aimed to determine the safety and efficacy of combining a janus kinase (JAK)‐inhibitor with ibrutinib
Publikováno v:
EBioMedicine
EBioMedicine, Vol 15, Iss C, Pp 24-35 (2017)
EBioMedicine, Vol 15, Iss C, Pp 24-35 (2017)
Recent studies suggest there is a high incidence of elevated low-density lipoprotein (LDL) levels in Chronic Lymphocytic Leukemia (CLL) patients and a survival benefit from cholesterol-lowering statin drugs. The mechanisms of these observations and t
Autor:
Guizhei Wang, David Spaner, Stephanie Tung, Sina Oppermann, Jarkko Ylanko, David W. Andrews, Yonghong Shi, Brian Leber, Lindsay McCaw, Avery J. Lam
Publikováno v:
Oncotarget
Glucorticoids (GCs) such as dexamethasone (DEX) remain important treatments for Chronic Lymphocytic Leukemia (CLL) but the mechanisms are poorly understood and resistance is inevitable. Proliferation centers (PC) in lymph nodes and bone marrow offer
Autor:
Yonghong Shi, Patricia Disperati, Guizhei Wang, Yanmei Li, Lindsay McCaw, Mary-Ann Cussen, David Spaner
Publikováno v:
Haematologica. 101:e192-e195
B cell receptor (BCR)-signaling inhibitors such as Ibrutinib and Idelalisib do not cure CLL, suggesting the importance of other pathways.1 Cytokines are also important in CLL biology and mediate transcription of oncogenic genes such as miR-17 by acti
Autor:
Jennifer A. Woyach, Georg A. Bjarnason, Guizhi Wang, David Spaner, Lindsay McCaw, Yonghong Shi, Catherine Wang, Elizabeth M. Muhowski
Publikováno v:
Leukemia. 33(7)
Glucocorticoid (GC) receptor (GR) phosphorylation and signature genes were studied in chronic lymphocytic leukemia (CLL) cells to help place GCs within modern treatment algorithms. In contrast to normal B and T cells, transcription of GC-regulated ge
Autor:
Yanmei Li, You-Jun Li, Burton B. Yang, Lindsay McCaw, R.M. Gorczynski, Fang Zhu, Gordon Duncan, Yaacov Ben-David, Yonghong Shi, David Spaner
Publikováno v:
Blood. 126:766-778
The regulation of toll-like receptor (TLR) signaling in a tumor microenvironment is poorly understood despite its importance in cancer biology. To address this problem, TLR7-responses of chronic lymphocytic leukemia (CLL) cells were studied in the pr
Publikováno v:
Leukemia research. 66
The tumor microenvironment (TME) is critical to the longevity of tumor B cells in chronic lymphocytic leukemia (CLL). Bone marrow mesenchymal stem cells (BMMSCs) and the cytokines they produce including IL-6 are important components of the TME in CLL